Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema. The FDA previously approved ranibizumab (Lucentis, Roche) for the same indication.

Eylea (aflibercept) injection is also indicated for treatment of which of the following?

A. Neovascular age-related macular degeneration

B. Macular edema following retinal vein occlusion

C. Both of the above

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Have You Heard This (Week's) News?

Newsletter